NCT00214838

An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 61 (planned)
• Sponsor: Callisto Pharmaceuticals · Industry
• Sex: All
• Age: 13 Years
• Healthy volunteers: Not accepted

Summary

The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer.

Detailed description

The primary objectives of this study are to identify the maximum tolerated dose(MTD) and to evaluate safety of atiprimod in patients with advanced cancer. The secondary objectives of this study are 1) to measure the pharmacokinetics of atiprimod and 2) to evaluate the efficacy of atiprimod treatment in patients with advanced cancers and 3) to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues.

Conditions

• Advanced Cancer

Interventions

Type	Name	Description
DRUG	Atiprimod

Timeline

• Start date: 2005-03-01
• Completion: 2007-03-01
• First posted: 2005-09-22
• Last updated: 2006-12-05

Locations

1 site across 1 country: United States